Long-term Efficacy of Microwave Hyperthermia Combined with Chemoradiotherapy in Treatment of Nasopharyngeal Carcinoma with Cervical Lymph Node Metastases

Kang, Min; Liu, Wenqi; Qin, Ya‐Zhen; Wei, Zhu‐Xin; Wang, Rensheng

doi:10.7314/apjcp.2013.14.12.7395

Cited by 23 publications

(28 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate of CR (3.9%) and PR (53.0%) in control group was similar with 4.3% and 51.7% reported by Zeng (2014). The CR rate 85% of patients following radiotherapy was higher than 50.0% in control group and 64.3% reported in the literature (Kang et al 2013) after dose-dense chemotherapy. And the median 0S, survival rate in 2 and 3 year were increased for 19.1months, 39.1% and 47.4% than control group.…”

Section: Discussionsupporting

confidence: 85%

Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil

Bu¹,

Cheng²,

Gao³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Purpose: To investigate the efficacy and safety of selective radiotherapy after distant metastasis of nasopharyngeal carcinoma (NPC) treated with dose-dense cisplatin plus fluorouracil. Materials and Methods: Eligible patients were randomly assigned to a study group treated with dose-dense cisplatin plus fluorouracil following selective radiotherapy and a control group receiving traditional cisplatin plus fluorouracil following selective radiotherapy according to a 1:1 distribution using a digital random table method. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival (PFS), objective response rate, relapse or progression rate in the radiation field and treatment toxicity. Results: Of 52 patients in the study group, 20 cases underwent radiotherapy., while in the control group of 51 patients, 16 underwent radiotherapy. The median PFS, median OS, survival rates in 1, 2 and 3 years in study and control group were 20.9 vs 12.7months, 28.3 vs 18.8months, 85.2%vs 65.9%, 62.2% vs 18.3%, and 36.6%vs 5.2% (p values of 0.00, 0.00, 0.04, 0.00 and 0.00, respectively). Subgroup analysis showed that the median OS and survival rates of 1, 2, 3 years for patients undergoing radiotherapy in the study group better than that in control group( 43.2vs24.1 months, 94.1% vs 86.7%, 82.4% vs 43.3%, 64.7% vs 17.3%, (p=0.00, 0.57, 0.04 and 0.01, respectively). The complete response rate, objective response rate after chemotherapy and three months after radiotherapy, relapse or progression rate in radiation field in study group and in control group were 19.2% vs 3.9%, 86.5% vs 56.9%, 85% vs 50%, 95% vs 81.3% and 41.3% vs 66.7% (p =0.03, 0.00, 0.03,0.30, 0.01 respectively). The grade 3-4 acute adverse reactions in the study group were significantly higher than in the control group (53.8% vs 9.8%, p=0.00). Conclusions: The survival of patients benefits from selective radiotherapy after distant metastasis of NPC treated with dose-dense cisplatin plus fluorouracil.

show abstract

Section: Discussionsupporting

confidence: 85%

Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil

Bu¹,

Cheng²,

Gao³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Mean achieved temperature profiles differed vastly between 39 and 43°C. In trials using multiple HT specification, higher temperatures or HT frequencies were associated with better outcome (88, 100, 116). This underlines the necessity of optimizing HT schedules to optimize the treatment effect.…”

Section: Discussionmentioning

confidence: 99%

“…Three other randomized trials with a total of 417 patients recently analyzed the effects of trimodal treatment combing RT, CT, and HT in patients with nasopharyngeal carcinomas (88–90). Two studies reporting CR showed a significant advantgae for RTHTCT treatment.…”

Section: Clinical Evidence Of Combined Thermoradiotherapymentioning

confidence: 99%

“…Progression-free survival (PFS) or disease-free survival (DFS) was significantly better in the RTHTCT group in all three studies. Patients with higher tumor temperatures and higher HT fraction numbers showed a better outcome (88). In all three studies, no difference in treatment-related toxicity has been described.…”

Section: Clinical Evidence Of Combined Thermoradiotherapymentioning

confidence: 99%

See 1 more Smart Citation

Integrating Hyperthermia into Modern Radiation Oncology: What Evidence Is Necessary?

2017

View full text Add to dashboard Cite

Hyperthermia (HT) is one of the hot topics that have been discussed over decades. However, it never made its way into primetime. The basic biological rationale of heat to enhance the effect of radiation, chemotherapeutic agents, and immunotherapy is evident. Preclinical work has confirmed this effect. HT may trigger changes in perfusion and oxygenation as well as inhibition of DNA repair mechanisms. Moreover, there is evidence for immune stimulation and the induction of systemic immune responses. Despite the increasing number of solid clinical studies, only few centers have included this adjuvant treatment into their repertoire. Over the years, abundant prospective and randomized clinical data have emerged demonstrating a clear benefit of combined HT and radiotherapy for multiple entities such as superficial breast cancer recurrences, cervix carcinoma, or cancers of the head and neck. Regarding less investigated indications, the existing data are promising and more clinical trials are currently recruiting patients. How do we proceed from here? Preclinical evidence is present. Multiple indications benefit from additional HT in the clinical setting. This article summarizes the present evidence and develops ideas for future research.

show abstract

“…Hyperthermia combined with radiotherapy or chemotherapy can increase the drug concentration in tumour cells or reduce the required radiation dose, thus augmenting anticancer effects and mitigating side effects. The long-term efficacy of microwave hyperthermia combined with chemoradiotherapy for treating NPC with metastatic foci in cervical lymph nodes was evaluated by Kang et al [6]. It has been shown that microwave hyperthermia combined with chemoradiotherapy can increase local control, disease-free survival and 3-and 5-year overall survival rates of patients with N2 $ N3 stage NPC.…”

Section: Introductionmentioning

confidence: 99%

Magnetic nanoparticle clusters radiosensitise human nasopharyngeal and lung cancer cells after alternating magnetic field treatment

Zhang

et al. 2015

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

Long-term Efficacy of Microwave Hyperthermia Combined with Chemoradiotherapy in Treatment of Nasopharyngeal Carcinoma with Cervical Lymph Node Metastases

Cited by 23 publications

References 15 publications

Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil

Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil

Integrating Hyperthermia into Modern Radiation Oncology: What Evidence Is Necessary?

Magnetic nanoparticle clusters radiosensitise human nasopharyngeal and lung cancer cells after alternating magnetic field treatment

Contact Info

Product

Resources

About